IHC-Bond, IHC-P
H
Endogenous
Mouse IgG1 kappa
#P40967
6490
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| IHC Leica Bond | 1:800 - 1:3200 |
| Immunohistochemistry (Paraffin) | 1:400 - 1:1600 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with extract of pigmented melanoma metastases from lymph nodes.
Background
PMEL/Melanoma gp100 is a type 1 transmembrane glycoprotein primarily expressed in pigment cells of the skin and eye, and overexpressed in more than 75% of human melanomas (1-3). It is involved in the transformation of melanosomes from stage I to stage II, forming the fibrillar matrix necessary for pigmentation of the cell (4). The synthesis and modification of PMEL/Melanoma gp100 is done in the endoplasmic reticulum (ER) and transferred to the Golgi complex where it is cleaved into two disulfide-linked subunits, Mα and Mβ. The cleavage of the large luminal Mα fragment is required for the formation of the fibrils that are the structure for melanin synthesis (5,6). The ability for PMEL/Melanoma gp100 to form functional amyloids makes it an interesting protein to study when looking at pathological amyloids in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease (5,7). Due to melanocyte-restricted expression of this protein, PMEL/Melanoma gp100 is considered a tumor-associated antigen that can be targeted by immunotherapeutic approaches to treat melanoma (8-10).
- Theos, A.C. et al. (2005) Pigment Cell Res 18, 322-36.
- Cormier, J.N. et al. (1998) J Immunother 21, 27-31.
- Robila, V. et al. (2008) J Immunol 181, 7843-52.
- Hoashi, T. et al. (2006) J Biol Chem 281, 21198-208.
- Bissig, C. et al. (2016) Int J Mol Sci 17, 1438.
- Berson, J.F. et al. (2001) Mol Biol Cell 12, 3451-64.
- van Niel, G. (2016) Cell Mol Neurobiol 36, 327-42.
- Schwartzentruber, D.J. et al. (2011) N Engl J Med 364, 2119-27.
- Baba, T. et al. (2010) J Transl Med 8, 84.
- Lesterhuis, W.J. et al. (2011) Cancer Immunol Immunother 60, 249-60.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
IHC-Bond: IHC Leica Bond IHC-P: Immunohistochemistry (Paraffin)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
